MediciNova Presents Examine Replace and Interim Evaluation of Section 2/3 Scientific Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Scientific Trial) on the thirty fifth Worldwide Symposium on ALS/MND By Investing.com
LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova (NASDAQ:), Inc.,…
